← All indications
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
Subtype terms (2)
More specific conditions that are subtypes of Renal Insufficiency, Chronic in the MeSH hierarchy.
- Chronic Kidney Diseases of Uncertain Etiology
- Kidney Failure, Chronic
663 drugs (369 approved, 294 experimental)
Drugs by status
Approved for this indication (19)
Phase 4 trials (149)
- hydroxychloroquine
- ombitasvir
- pitavastatin
- fosinopril
- ambrisentan
- acetylsalicylic acid
- simvastatin
- nebivolol
- grazoprevir
- ezetimibe
- nitrendipine
- empagliflozin
- bumetanide
- icodextrin
- iron
- prednisone
- valsartan
- allopurinol
- aliskiren
- desidustat
- sugammadex
- pibrentasvir
- furosemide
- alprostadil
- warfarin
- zirconium silicate
- sarpogrelate
- abacavir
- iopromide
- apixaban
- +119 more
Phase 3 trials (76)
- qrx-3
- bion-1301
- multivitamins
- metoprolol
- anakinra
- raltegravir
- denosumab
- pegol-sihematide
- ly3502970
- magnesium sulfate
- aprocitentan
- risedronate
- cytarabine
- bi 690517
- ferric sulfate
- nitrofurantoin
- zinc
- bnt162b2
- pu yang wan wu tang
- iron oligosaccharide
- Veverimer
- insulin lispro
- vasopressin
- blood plasma
- ferric derisomaltose
- nemolizumab
- darbepoetin beta
- omega-3 fatty acids
- dulaglutide
- peginesatide
- +46 more
Phase 2 trials (90)
- acsdkp-nh2 inuline
- propolis
- metolazone
- lactobacillus plantarum
- urea
- bi 764198
- ctp-499
- sacubitril
- cotadutide
- thalidomide
- rutin
- rifampin
- pectin
- autologous neo-kidney augment
- baricitinib
- tour006
- measles, mumps, rubella, varicella vaccine
- azd5718
- zibotentan
- mdgn201
- mesna
- verinurad
- autologous mesenchymal stem cells
- whey protein
- nitric oxide
- dasatinib
- chitosan
- azd2373
- bendamustine
- autologous selected renal cells
- +60 more
Phase 1 trials (55)
- quetiapine
- stannous protoporphyrin
- cannabidiol
- autologous, homologous, selected renal cells
- autologous adipose-derived mesenchymal stem cells
- tetrahydrocannabinol
- phosphate
- flucloxacillin
- ddo-3055
- ly3113593
- ad-214
- gosogliptin
- pegylated carboxyhemoglobin
- stiripentol
- ts-143
- bosutinib
- diclofenac
- vx-840
- dm199
- allorx stem cells®
- apraglutide
- hec53856
- nnc0705-0001
- adomeglivant
- tq-b3525
- azd4248
- kdstem.
- ctap201
- yg1699
- bq-123
- +25 more
Other trials (83)
- probucol
- vitamin k
- dark chocolate
- daptomycin
- ginseng
- canola oil
- para-cresol
- cranberry
- olive
- prilocaine
- fish oil
- mepivacaine
- montelukast
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- benzbromarone
- acetylcholine chloride
- almond
- sodium thiosulfate
- levocarnitine
- huang qi gui zhi wu
- phenylephedrine
- sertraline
- linagliptin
- kibow biotics
- vitamin k2
- pomegranate
- blueberry
- flax
- tyrosine
- Lactobacillus acidophilus
- +53 more
Organizations
Organization Involved with Phase 4 Indications (213)
- Yuhan Pharmaceutical Company
- St. Marianna University School of Medicine
- Shaanxi University of Chinese Medicine
- Parexel
- University of Oxford
- Second Military Medical University
- NephroNet Clinical Research Consortium
- Hanmi Pharmaceutical
- Erasmus University Rotterdam
- Ardelyx
- Maisonneuve-Rosemont Hospital
- National Health and Medical Research Council, Australia
- Barts & The London NHS Trust
- Southeast University
- Teva
- People's Liberation Army of China
- University of Colorado, Denver
- Johnson and Johnson
- Hospital Aleman
- University of Birmingham
- Tufts University
- Albany College of Pharmacy and Health Sciences
- University of Munster
- University of Delaware
- University of Michigan
- Osaka University
- General Electric
- University of Naples Frederico II
- Wyeth
- Corporacion Parc Tauli
- +183 more
Organization Involved with Phase 3 Indications (171)
- The Physicians' Services Incorporated Foundation
- Thammasat University
- Tokushukai Medical Group
- Daping Hospital
- National Institutes of Health (NIH)
- Nabi Biopharmaceuticals
- East Kent Hospitals University NHS Foundation Trust
- Corbridge Group Philippines, Inc.
- University of Chile
- Bio Sidus SA
- University of Heidelberg
- Taipei Veteran General hospital
- University of Applied Sciences Utrecht
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- University of Milan
- University of Nice Sophia Antipolis
- Fondazione Toscana Gabriele Monasterio
- Tonghua Central Hospital
- University of Goettingen
- University of Durham
- Qingdao University
- University of Alberta
- Peking University
- North Zealand Hospital
- Thomas Jefferson University
- Shield Therapeutics
- CorMedix
- Assiut University
- Vifor Inc.
- American Society of Nephrology
- +141 more
Organization Involved with Phase 2 Indications (86)
- Institut National de la Santé Et de la Recherche Médicale, France
- Chaitanya Hospital
- Pieris Pharmaceuticals GmbH
- Mahidol University
- Fangshan Hospital of Traditional Chinese Medicine
- RegenMed
- University of Reims
- Columbia University
- Sunshine Lake Pharma Co., Ltd.
- KAI Pharmaceuticals
- Pharmaterra
- Bangladesh Laser & Cell Surgery Institute & Hospital
- Encysive
- Regeneron
- ZS Pharma, Inc.
- Anesiva, Inc.
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Institute of Clinical and Experimental Medicine Nephrology Clinic Prague
- Johns Clinical Consulting
- Global Blood Therapeutics, Inc.
- A2 Healthcare Taiwan Corporation
- Sorbent Therapeutics
- Lantheus Medical Imaging
- Alexion
- University of Ulm
- University of Paris
- Tanta University
- Veterans Medical Research Foundation
- Cara Therapeutics
- Government of Netherlands
- +56 more
Organization Involved with Phase 1 Indications (43)
- University of Utah
- Rio de Janeiro State University
- Rockefeller University
- The Medicines Company
- Covance
- GNI Group
- Hengrui Therapeutics, Inc.
- Haisco Pharmaceutical
- Georgetown University
- Sarfez Pharmaceuticals, Inc.
- Rouen Normandy University
- Mazandaran University of Medical Sciences
- Government of Brazil
- California Institute of Renal Research, Inc.
- Akros
- RegenMedTx
- New Orleans Center for Clinical Research
- Harbin Medical University
- ClinSmart
- Southwest Clinical Research Institute, LLC
- University of Caen-Normandie
- University of Cincinnati
- FerruMax Pharmaceuticals, Inc.
- Federal University of Rio de Janeiro
- Regenerative Medicine Minnesota
- Vidasym, Inc.
- Orlando Clinical Research Center
- Savient Pharmaceuticals
- Renibus Therapeutics, Inc.
- University of Cologne
- +13 more
Organization Involved with Other Experimental Indications (61)
- National Institute of General Medical Sciences (NIGMS)
- Cairo University
- Gottfried Wilhelm Leibniz Universität Hannover
- American Diabetes Association
- University of California, Davis
- University of Oklahoma
- Wake Forest University
- University of Gothenburg
- University of Indonesia
- "Maggiore della Carità" Hospital
- Pennsylvania State University
- Nazareth Hospital
- Dialysis Clinic, Inc.
- Yuksek Ihtisas University
- Nazareth EMMS Hospital
- University of Vermont
- Centro Universitário Univates
- Probiotical S.p.A.
- The Nazareth Hospital, Israel
- Damanhour University
- Great Lakes Dialysis, LLC
- Tzu Chi University
- Government of Canada
- University of Eastern Piedmont
- FlowMedic
- Loma Linda University
- Cubist
- Dalin Tzu Chi General Hospital
- University of Bari
- University of California, Irvine
- +31 more